Insulet (PODD) Earnings Date & Reports

Key Takeaways

• Insulet reported third-quarter 2026 revenue of $842 million, up 19.2% year over year, edging above the roughly $833 million consensus estimate.
• Adjusted earnings per share came in at $1.99, well ahead of the $1.59 analyst consensus and up 27.5% from the prior-year period.
• The company posted record gross margin and expanded operating margin, reflecting manufacturing scale and productivity gains.
• Management narrowed its full-year 2026 revenue outlook to the top end of its prior range, while signaling a more conservative stance on 2027.
• The board approved a $1 billion increase to the share repurchase authorization, with about $400 million expected to be deployed in Q4.
• Get more detail on PODD's Major News, Today's Price Move, Price Targets, and Forecast on additional pages.
• Explore Trending AI Robots to see how AI-driven trading tools are navigating the current market.

Earnings Context and Why It Matters

Insulet, the global leader in tubeless insulin pump technology behind the Omnipod brand, delivered its Q3 2026 results against a backdrop of rising competitive intensity in the automated insulin delivery (AID) market. The report matters because it tests whether the company can sustain its top-tier growth while new rival products enter the category and type 2 diabetes retention remains a focus. Following a sharp selloff after its Q2 report, when management cut full-year guidance on softer U.S. type 2 trends, investors were watching closely for evidence that corrective actions were taking hold. Strong international momentum and margin expansion offered reassurance, while early 2027 commentary introduced fresh caution about the pace of future growth.

Reported Results

For the third quarter ended September 30, 2026, Insulet posted revenue of $842 million, an increase of 19.2% year over year, or 19.6% in constant currency. The figure modestly exceeded the consensus estimate of about $833 million. Adjusted earnings per share reached $1.99, comfortably beating the $1.59 consensus, while GAAP diluted earnings per share came in at $2.03, up from $1.24 a year earlier. Net income rose to $141.1 million from $87.6 million in the prior-year period.

Total Omnipod revenue was $836.6 million, up 19.7%. U.S. Omnipod revenue grew 14.7% to $570.4 million, while International Omnipod revenue climbed 31.7% to $266.2 million, up 33.0% in constant currency. The smaller Drug Delivery segment declined 22.7% to $5.5 million. Operating income reached $189.8 million, or 22.5% of revenue, up 590 basis points year over year, helped by record gross margin and ongoing productivity improvements.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking earnings-driven movers like Insulet, it offers a structured way to surface comparable setups across the medical device sector and beyond.

Market Reaction and Investor Sentiment

Insulet shares responded cautiously to the report, with initial gains tempered by management's preliminary 2027 commentary. The headline beat on both revenue and earnings supported sentiment, as did the narrowed full-year 2026 guidance and the expanded buyback authorization. However, management indicated that 2027 total company growth is expected to come in modestly below its prior mid-teens framework, with U.S. growth toward the lower end of the 9% to 14% range and a meaningful slowdown internationally. That more conservative posture, tied to the timing of new product launches and a much larger revenue base, weighed on investor enthusiasm and reinforced the market's sensitivity to forward guidance rather than backward-looking beats.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will focus on how Insulet balances near-term execution with its longer-term innovation pipeline. The company has submitted the second and final 510(k) application for Omnipod 6 and continues to target a 2027 launch, positioning the next-generation platform as a key catalyst. Management framed the 2027 slowdown as a function of product-launch timing and scale, but the market will want clearer evidence that growth can re-accelerate once Omnipod 6 reaches full commercialization.

Several factors warrant monitoring in the coming quarters. First, type 2 diabetes retention remains central: management reported modest improvement in Q3 from its corrective action plan, including salesforce expansion, revised compensation, and onboarding enhancements. Sustained retention gains would support the U.S. growth outlook. Second, the ramp of Omnipod Discover, now adopted by more than 35,000 users, could strengthen engagement and loyalty. Third, investors will watch the remaining U.S. pharmacy benefit manager (PBM) contract renewals for 2027, which could shape broad access across the pharmacy channel.

Finally, cost trends and capital allocation will stay in focus. The record gross margin and expanded operating margin demonstrate the benefits of manufacturing scale, while the $1 billion buyback increase and planned $400 million Q4 repurchase signal management's confidence in cash generation. Balancing these reinvestments against a more dynamic competitive environment will be a defining theme heading into 2027.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations